26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Specimen Collection and Confirmation of Norovirus Outbreaks1

      brief-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We evaluated data from gastroenteritis outbreaks in Oregon to assess sensitivity of stool testing for norovirus and determine number of specimens needed to confirm norovirus as the cause. Norovirus can be readily confirmed if 3–6 specimens are collected any time <7 days after onset of diarrhea and for almost that long after symptoms resolve.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: not found

          Norwalk Virus Shedding after Experimental Human Infection

          Noroviruses are the most common cause of epidemic gastroenteritis in the United States ( 1 ). Although in vitro replication systems for these viruses have recently been described ( 2 , 3 ), human noroviruses cannot readily be grown in cell culture, and no small animal model of human norovirus infection is available. Much of what is known about these viruses has by necessity been learned from experimental human infection and from observational studies of naturally acquired infection. Norwalk virus is the prototype strain in the genus Norovirus, and many of the human experimental infection studies have used this strain ( 4 – 9 ). We describe the duration and magnitude of virus shedding in persons infected with Norwalk virus after experimental inoculation. Materials and Methods Virus Inoculum Liquid feces from persons who participated in a previous Norwalk virus challenge study ( 8 ) were screened to identify samples with high concentrations of Norwalk virus RNA (>107 reverse transcription–PCR [RT-PCR] U/mL). The participants were recontacted and screened for health (results within normal limits for liver function, tuberculosis skin test [negative], and chest radiographs; negative serologic test results for hepatitis A, B, and C, retroviruses [HIV-1, HIV-2, and human T-lymphotropic virus 1 and 2], and syphilis [nonreactive rapid plasma regain]). The new challenge inoculum (lot 42399) was prepared from liquid feces of 1 participant by clarification, centrifugation, and serial filtration through filters with progressively smaller pore size to a final 0.45-μm filter size. The inoculum, which contained no other enteric viruses or adventitious agents, was packaged and stored at –80°C. Challenge Protocol Challenge studies were conducted from September 2004 through October 2006. Healthy adults (18–50 years of age) provided informed consent and successfully completed a test of understanding. In addition, eligible persons were secretor positive (because secretor-negative persons are resistant to Norwalk virus infection; 9 , 10 ), had screening laboratory study results that were within normal limits (liver and renal function, blood counts), had negative serologic results for hepatitis and HIV, had no serious chronic diseases, had no history of nonbacterial gastroenteritis within 3 months of inoculation or of bacterial or protozoal enteric infection within 1 month (based on 3 negative enteric cultures and fecal ova and parasite studies in the 4-week preinoculation screening period), were not exposed to persons considered to be at risk for more severe norovirus infection (e.g., immunocompromised patients, the elderly, and children), and were not employed in jobs identified as having high risk for transmission to other persons (e.g., food service, healthcare, and airline industries). On the day of inoculation, participants were admitted to the Baylor College of Medicine General Clinical Research Center and orally received different dosages of inoculum (10-fold dilutions ranging from 4.8 to 4,800 RT-PCR units) or placebo in the early evening. Inoculated participants remained in the Center for a minimum of 96 hours and at discharge had experienced no watery feces or vomiting for at least 18 hours. Participants’ clinical signs and symptoms were evaluated every 4 hours while they were in the Center, and all fecal samples were collected and refrigerated immediately. Within 24 hours of collection, the samples were transported to the laboratory for processing and stored at –70oC until analyzed. After patient discharge, all fecal samples were collected daily for 21 days and then weekly for up to 5 additional weeks (for a total observation time of up to 8 weeks postinoculation). The samples were delivered to the laboratory within a day of collection and were processed and stored as described above. Participants were educated about the importance of hand washing and hand hygiene at the beginning of the study, and these concepts were reinforced at each study visit. The clinical protocol was reviewed and approved by the Institutional Review Board at Baylor College of Medicine, and an Investigational New Drug application describing the clinical protocol and study inoculum was reviewed by the US Food and Drug Administration. Laboratory Studies Norwalk virus–specific antigen was detected by sandwich ELISA, using Norwalk virus–specific antiserum, as previously described ( 8 ), and Norwalk virus–specific antibody was detected by ELISA, using Norwalk virus–like particles as antigen, as previously described ( 8 ). Norwalk virus RNA was detected in fecal specimens by using either an immunomagnetic capture (IMC) RT-PCR assay ( 11 ) or quantitated by real-time RT-PCR (qRT-PCR) with RNA transcripts as a standard ( 2 ). The primers used for the IMC RT-PCR assay were the antisense Norwalk virus p35 (5′-CTT GTT GGT TTG AGG CCA TAT-3′) and the sense Norwalk virus p36 (5′-ATA AAA GTT GGC ATG AAC A-3′); probe was a 5′ digoxigenin-labeled Norwalk virus p69 (5′-GGC CTG CCA TCT GGA TTG CC-3′). For the qRT-PCR assay, a 10% fecal sample was diluted 1,000-fold and heated to 95oC for 5 min ( 12 ); 20 μL of heated sample was analyzed in duplicate wells. The primers for the qRT-PCR assay were the antisense Norwalk virus p165 (5′-CAT AAT CAC CTA CAT CCA TCT CAG ATG-3′, which is complementary to Norwalk virus nt 4689–4715) and the sense primer Norwalk virus p166 (5′-CGG CCT CAC CAG AAT TGG-3′, which is complementary to Norwalk virus nt 4641–4658); the probe was Norwalk virus p167 (5′-FAM/CGA GGT TGT GGC CCA AGA TTT GCT AG/TAMRA-3′, which is complementary to nt 4660–4685). For determination of a virus titer, both wells had to show amplification. The limits of detection for the IMC RT-PCR and qRT-PCR assays were ≈15 × 103 and ≈40 × 106 copies/g feces, respectively. Definitions Infection was defined as seroresponse (4-fold rise in titer from preinoculation baseline to 30-day serum sample, as measured by ELISA) or fecal virus excretion as detected by RT-PCR or presence of antigen. Viral gastroenteritis was defined as illness with moderate diarrhea (alone) for any continuous 24-hour period (moderate diarrhea is >200 g of watery feces that immediately take the shape of the collection container) or 1 vomiting episode plus 1 of the following: abdominal cramps or pain, nausea, bloating, loose feces (if not fulfilling the definition of diarrhea), fever (oral temperature >37.6°C), myalgia, or headache. Results A total of 16 persons inoculated with Norwalk virus met the criteria for having Norwalk virus infection. Of these, 11 (69%) met the predefined definition for viral gastroenteritis. The 5 who did not meet this predefined definition had >3 symptoms that did not include vomiting or >200 g of watery diarrhea. All 11 participants with viral gastroenteritis had abdominal cramps, nausea, and vomiting; 5 of these participants also had >200 g of watery diarrhea, and 1 had 37.6oC (n = 4), and chills (n = 3). The 5 participants who did not fulfill the criteria for gastroenteritis had nausea (n = 5), anorexia (n = 5), malaise (n = 4), abdominal cramps (n = 3), myalgia (n = 3), headache (n = 3), temperature >37.6oC (n = 2), chills (n = 2), and watery diarrhea 4-fold rise in serum antibody level, and all but 2 also shed virus as measured by antigen ELISA (Table). Virus shedding as measured by IMC RT-PCR was first detected a median of 36 hours (range 18–110 hours) after inoculation and lasted a median of 28 days after inoculation (range 13–56 days). Norwalk virus was detected in fecal samples of 7 participants 3–14 hours before onset of any clinical signs or symptoms. Presymptomatic shedding was more common in persons who did not meet the definition of clinical gastroenteritis than in those who did (4/5 vs. 3/11, respectively, p = 0.11, 2-tailed Fisher exact test). Virus shedding as measured by antigen ELISA was first detected ≈33 hours (median 42 hours) after inoculation and was last detected 10 days (median 7 days) after inoculation. Median values of the onset and resolution of virus shedding, as measured by IMC RT-PCR or antigen ELISA, were similar for the participants who had clinical gastroenteritis compared with those of persons who did not meet the definition of gastroenteritis (Table). Table Fecal virus shedding among 16 participants inoculated with Norwalk virus* Participant no. Estimated Norwalk virus inoculum dose (RT-PCR units) First–last study days† postinoculation when symptoms present First–last study days IMC 
RT-PCR positive Day peak virus titer (character of feces) Peak qRT-PCR virus titer (log10/g) First–last study days postinoculation when antigen positive Met clinical definition of gastroenteritis Had diarrhea and vomiting 706 4,800 2 2–28‡ 2 (liquid) 11.1 2–9 707 4,800 2–4 1–30‡ 2 (liquid) 9.5 4–8 710 4,800 1–2 2–30‡ 5 (solid) 10.9 2–7 722 48 2 2–48 4 (solid) 11.7 2–8 724 4.8 2–3 2–56 3 (solid) 11.4 2–6 Had vomiting only 701 4,800 1–2 1–29‡ 4 (solid) 10.8 3–10 720§ 48 2 2–56 4 (solid) 11.5 2–9 721 48 1–3 2–21 4 (solid) 11.7 2–10 723 48 2 1–50 4 (solid) 12.2 2–6 731 4.8 2–3 5–10 5 (solid) 10.0 None 732 4.8 2–3 2–15 3 (solid) 11.9 2–6 Median – 2 2–30‡ 4 (solid) 11.4 2–8 Did not meet clinical definition of gastroenteritis 703 4,800 2–3 1–32‡ 2 (solid) 10.7 2–9 704 4,800 2–3 4–21‡ 5 (solid) 9.2 5–7 715§ 48 2–3 1–28 3 (solid) 11.7 2–5 716§ 48 2–3 1–20 4 (unformed) 10.1 3–7 717 48 3 4–13 4 (solid) 9.3 None Median – 2–3 1–21‡ 4 (solid) 10.1 2–7 *RT–PCR, reverse transcription–PCR; IMC, immunomagnetic capture; qRT-PCR, quantitative PCR.
†Study days are reported as calendar days; study day 1 began ≈5–6 h postinoculation.
‡Fecal samples only collected for 30 d postinoculation.
§Watery feces with mass 100 × 106 copies/g until at least day 14 (Figure 1). Persons who met the clinical definition of gastroenteritis had a higher median peak of virus shedding than those who did not have gastroenteritis (250 × 109 vs. 12 × 109 genomic copies/g feces, p = 0.08, Wilcoxon rank sum), and the average total number of viral genomic copies measured in the feces over the first 2 weeks after inoculation also was higher in the clinical gastroenteritis group (1013.3 vs. 1012.4, p = 0.056, Student t test). The virus concentrations in feces collected later after inoculation were low (range 225,000–40 × 106 genomic copies/g). Correlation between virus titer in feces and optical density results obtained in the antigen ELISA was strong (r = 0.823, Pearson correlation, p 1011 norovirus copies/g feces, whereas the peak fecal virus titer observed by Ozawa et al. ( 18 ) in symptomatic and asymptomatic food handlers was ≈10-fold lower. Each of these studies was of persons with naturally acquired norovirus infection. However, the median peak viral load observed in our study (1011) was much higher than the 107–108 median viral loads reported in the prior studies ( 17 , 18 ). Lee et al. ( 19 ) noted higher viral loads in patients who had more prolonged symptoms (>4 days) associated with infection caused by GII.4 norovirus. Amar et al. ( 20 ) also reported viral loads to be higher in persons who had symptomatic gastroenteritis than in those who had been asymptomatic for at least 3 weeks. Our findings suggest that clinical gastroenteritis was associated with higher peak virus shedding and higher total virus shedding during the first 2 weeks after inoculation. Although we did not see an association of peak virus titer with symptom duration, the median duration of symptoms averaged only ≈1 day in our study. Potential reasons for the different results observed in other studies include the manner in which samples were collected (single samples vs. serial collection), the real-time assays used (generic assays designed to be broadly reactive vs. assay designed specifically for Norwalk virus detection), virulence of the infecting strains, differences in the populations studied (e.g., age, immune status), and the small number of infected persons who did not have clinical gastroenteritis in our study. The development of more sensitive methods to detect noroviruses has been associated with a corresponding increase in the duration of recognized virus shedding ( 1 , 8 ). For example, Rockx et al. ( 21 ) found norovirus in fecal samples for >3 weeks in ≈25% of infected persons, and Murata et al. ( 22 ) found norovirus in fecal samples for up to 6 weeks in infected infants. In contrast, at least half of the participants in our study still had Norwalk virus in fecal samples after 4 weeks and 2 had virus still present at 8 weeks; we cannot exclude the possibility that these 2 persons shed for a longer period. Determination of whether the virus is still infectious must await the development of more sensitive and reproducible methods for norovirus cultivation than are currently available ( 23 ).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Use of TaqMan real-time reverse transcription-PCR for rapid detection, quantification, and typing of norovirus.

            Noroviruses (NoVs) are the most commonly identified cause of outbreaks and sporadic cases of acute gastroenteritis. We evaluated and optimized NoV-specific TaqMan real-time reverse transcription (RT)-PCR assays for the rapid detection and typing of NoV strains belonging to genogroups GI and GII and adapted them to the LightCycler platform. We expanded the detection ability of the assays by developing an assay that detects the GIV NoV strain. The assays were validated with 92 clinical samples and 33 water samples from confirmed NoV outbreaks and suspected NoV contamination cases. The assays detected NoV RNA in all of the clinical specimens previously confirmed positive by conventional RT-PCR and sequencing. Additionally, the TaqMan assays successfully detected NoV RNA in water samples containing low viral concentrations and inhibitors of RT and/or PCR, whereas the conventional method with region B primers required dilution of the inhibitors. By means of serially diluted NoV T7 RNA transcripts, a potential detection limit of <10 transcript copies per reaction mixture was observed with the GII assay and a potential detection limit of <100 transcript copies per reaction mixture was observed with the GI assay. These results and the ability to detect virus in water that was negative by RT-PCR demonstrate the higher sensitivity of the TaqMan assay compared with that of a conventional RT-PCR assay. The TaqMan methods dramatically decrease the turnaround time by eliminating post-PCR processing. These assays have proven useful in assisting scientists in public health and diagnostic laboratories report findings quickly to outbreak management teams.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Detection and differentiation of antigenically distinct small round-structured viruses (Norwalk-like viruses) by reverse transcription-PCR and southern hybridization.

              Application of reverse transcription (RT)-PCR to detect small round-structured viruses (SRSVs) from fecal specimens of patients with gastroenteritis has been insensitive because of the tremendous sequence heterogeneity between strains. We have designed two RT-PCR primer sets (G-1 and G-2) based on the nucleotide sequence diversity in the RNA polymerase gene of SRSVs belonging to two distinct genogroups represented by Norwalk virus (primers G-1) and Snow Mountain agent (primers G-2). All 22 SRSV strains examined that had been classified previously by solid-phase immune electron microscopy into four antigenic types (UK1, UK2, UK3, and UK4) could be detected by RT-PCR with these two primer sets. The G-1 primer set detected 6 UK2 strains, and the G-2 primers detected 16 strains, including 7 UK1, 5 UK3, and 4 UK4 strains. On the basis of nucleotide sequences of 81-bp fragments of the RT-PCR products from 13 strains determined in this study, together with those previously reported for 17 SRSV strains, we designed four sets of internal oligonucleotide probes (P1-A, P1-B, P2-A, and P2-B) for Southern hybridization, using chemiluminescent detection. The P1-A probe hybridized with PCR products from the UK2 strains; the P1-B probe, with products from two of the seven UK1 strains; the P2-A probe, with four of the remaining five UK1 strains; and the P2-B probe, with products from both UK3 and UK4 strains, as well as with one strain originally typed as UK1 which showed cross-reactivity with UK4 upon retesting by solid-phase immune electron microscopy. RT-PCR with both the G-1 and the G-2 primer sets can increase the detection rate of the many antigenically distinct SRSVs and, when combined with Southern hybridization, may predict the antigenic type of the SRSV associated with infection.
                Bookmark

                Author and article information

                Journal
                Emerg Infect Dis
                Emerging Infect. Dis
                EID
                Emerging Infectious Diseases
                Centers for Disease Control and Prevention
                1080-6040
                1080-6059
                August 2011
                : 17
                : 8
                : 1553-1555
                Affiliations
                [1]Author affiliation: Oregon Department of Human Services, Portland, Oregon, USA
                Author notes
                Address for correspondence: Paul R. Cieslak, Acute and Communicable Disease Prevention, 800 NE Oregon St, Suite 772, Portland, OR 97232, USA; email: paul.r.cieslak@ 123456state.or.us
                Article
                10-1815
                10.3201/eid1708.101815
                3381577
                21801649
                0e9ea306-d196-47c5-b7c5-95afb8168b4b
                History
                Categories
                Dispatch

                Infectious disease & Microbiology
                diarrhea,stool specimens,dispatch,outbreaks,viruses,norovirus
                Infectious disease & Microbiology
                diarrhea, stool specimens, dispatch, outbreaks, viruses, norovirus

                Comments

                Comment on this article